OTC · QTXB
QuantRx Biomedical Corporation
Healthcare · Medical - Instruments & Supplies
$0.00
Up+$0.00 (+400.00%)
Updated Aug 25, 2026, 8:47 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 118.05K
- P/E ratio
- -0.08
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 22.1K
- Avg. volume
- 24.98K
Price performance
QTXB price history
1M range · 0 trading sessions · Daily adjusted prices
QTXB does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest QTXB news
The latest Smart Investors Daily articles mentioning QTXB.
Stock researchCompany · Overview
QTXB research
Overview
Company profile and research snapshot.
Company profile
QuantRx Biomedical Corporation engages in the development and commercialization of patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its products include InSync, a feminine hygienic interlabial pad; Unique miniform, a treated pad for the temporary relief of the itch and discomfort associated with hemorrhoids and minor vaginal infection, as well as an untreated pad for the daily protection of light urinary, vaginal, or anal leakage; and other treated miniform products. QuantRx Biomedical Corporation was incorporated in 1986 and is based in Tualatin, Oregon.
Analyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.

